Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
CTXR Citius Pharmaceuticals Inc
- Stocks
- Healthcare
- NASDAQ: CTXR
Price (delayed)
$0.724
Market cap
$7.45M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$5.79
Enterprise value
$8.32M
Citius is a late-stage specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care.
Highlights
The EPS is up by 5% year-on-year
CTXR's debt has soared by 149% YoY
Citius Pharmaceuticals's quick ratio has shrunk by 100% QoQ and by 100% YoY
Key stats
What are the main financial stats of CTXR
Market
Valuations
Earnings
Shares outstanding
10.29M
Market cap
$7.45M
Enterprise value
$8.32M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.1
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$42.98M
Net income
-$42.05M
EBIT
-$41.23M
EBITDA
-$41.01M
Free cash flow
-$23.55M
Per share
Balance sheet
Liquidity
EPS
-$5.79
EPS diluted
-$5.79
Free cash flow per share
-$2.74
Book value per share
$7.06
Revenue per share
$0
TBVPS
$13.07
Total assets
$121.48M
Total liabilities
$57.91M
Debt
$931,795
Equity
$60.66M
Working capital
-$31.5M
Debt to equity
0.02
Current ratio
0.37
Quick ratio
0
Net debt/EBITDA
-0.02
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-37.8%
Return on equity
-61.2%
Return on invested capital
-62.7%
Return on capital employed
-57.6%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CTXR stock price
How has the Citius Pharmaceuticals stock price performed over time
Intraday
6.31%
1 week
-12.55%
1 month
-11.72%
1 year
-96.1%
YTD
-81.9%
QTD
-51.41%
Financial performance
How have Citius Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$42.98M
Net income
-$42.05M
Gross margin
N/A
Net margin
N/A
The net income is down by 16% year-on-year and by 6% since the previous quarter
The operating income fell by 10% YoY
Price vs fundamentals
How does CTXR's price correlate with its fundamentals
Growth
What is Citius Pharmaceuticals's growth rate over time
Valuation
What is Citius Pharmaceuticals stock price valuation
P/E
N/A
P/B
0.1
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS is up by 5% year-on-year
The price to book (P/B) is 94% lower than the 5-year quarterly average of 1.6 and 88% lower than the last 4 quarters average of 0.8
Citius Pharmaceuticals's equity has decreased by 24% YoY and by 7% QoQ
Efficiency
How efficient is Citius Pharmaceuticals business performance
CTXR's ROE is down by 44% YoY and by 13% from the previous quarter
The ROIC has contracted by 11% YoY and by 7% from the previous quarter
Dividends
What is CTXR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CTXR.
Financial health
How did Citius Pharmaceuticals financials performed over time
Citius Pharmaceuticals's total assets is 110% higher than its total liabilities
Citius Pharmaceuticals's quick ratio has shrunk by 100% QoQ and by 100% YoY
Citius Pharmaceuticals's current ratio has shrunk by 93% YoY and by 10% QoQ
CTXR's debt is 98% lower than its equity
CTXR's debt has soared by 149% YoY
Citius Pharmaceuticals's equity has decreased by 24% YoY and by 7% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.